

# Joshua T Cohen

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8012525/joshua-t-cohen-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

145  
papers

5,693  
citations

36  
h-index

73  
g-index

154  
ext. papers

6,765  
ext. citations

6.1  
avg, IF

6.08  
L-index

#	Paper	IF	Citations
145	Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications.. <i>Value in Health</i> , <b>2022</b> , 25, 59-68	3.3	0
144	Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions.. <i>Genetics in Medicine</i> , <b>2022</b> ,	8.1	2
143	Drug-Pricing Debate Redux - Should Cost-Effectiveness Analysis Be Used Now to Price Pharmaceuticals?. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 1923-1924	59.2	3
142	Are Medical Devices Cost-Effective?. <i>Applied Health Economics and Health Policy</i> , <b>2021</b> , 1	3.4	0
141	Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines. <i>Vaccine</i> , <b>2021</b> , 39, 6727-6734	4.1	1
140	Value-based drug pricing in the Biden era: Opportunities and prospects. <i>Health Services Research</i> , <b>2021</b> , 56, 1093-1099	3.4	2
139	Dementia Diagnosis Disparities by Race and Ethnicity. <i>Medical Care</i> , <b>2021</b> , 59, 679-686	3.1	9
138	Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic. <i>Health Affairs</i> , <b>2021</b> , 40, 53-61	7	16
137	Targeting of the diabetes prevention program leads to substantial benefits when capacity is constrained. <i>Acta Diabetologica</i> , <b>2021</b> , 58, 707-722	3.9	1
136	Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 1972-1973	27.4	12
135	Balancing Value with Affordability: Cell Immunotherapy for Cancer Treatment in the U.S. <i>Oncologist</i> , <b>2020</b> , 25, e1117-e1119	5.7	4
134	Cost-Effectiveness of Brexanolone Versus Selective Serotonin Reuptake Inhibitors for the Treatment of Postpartum Depression in the United States. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2020</b> , 26, 627-638	1.9	6
133	Are low and middle-income countries prioritising high-value healthcare interventions?. <i>BMJ Global Health</i> , <b>2020</b> , 5, e001850	6.6	5
132	Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter?. <i>International Journal of Technology Assessment in Health Care</i> , <b>2020</b> , 36, 96-103	1.8	11
131	Racial and Ethnic Differences in Knowledge About One@ Dementia Status. <i>Journal of the American Geriatrics Society</i> , <b>2020</b> , 68, 1763-1770	5.6	7
130	The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e20019-e20019	2.2	0
129	Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 12068-12068	2.2	

128	Optimizing Decision Making in Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , <b>2020</b> , 265-273	0	1
127	Measuring "Fearonomic Effects" in Valuing Therapies: An Application to COVID-19 in China. <i>Value in Health</i> , <b>2020</b> , 23, 1405-1408	3.3	5
126	Hospital Care at Home: Better, Cheaper, Faster?. <i>Annals of Internal Medicine</i> , <b>2020</b> , 172, 145-146	8	0
125	Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018. <i>Pharmacoeconomics</i> , <b>2020</b> , 38, 1135-1145	11.45	33
124	Preparing the health-care system to pay for new Alzheimer's drugs. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, 1568-1570	1.2	6
123	Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs. <i>Journal of General Internal Medicine</i> , <b>2020</b> , 35, 2629-2636	4	17
122	Dementia diagnosis disparities by race and ethnicity. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e043183	1.2	4
121	Are National Comprehensive Cancer Network Evidence Block Affordability Ratings Representative of Real-World Costs? An Evaluation of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , <b>2019</b> , 15, e948-e956	3.1	11
120	Cost-effectiveness analysis of three algorithms for diagnosing primary ciliary dyskinesia: a simulation study. <i>Orphanet Journal of Rare Diseases</i> , <b>2019</b> , 14, 142	4.2	4
119	Publication of Decision Model Source Code: Attitudes of Health Economics Authors. <i>Pharmacoeconomics</i> , <b>2019</b> , 37, 1409-1410	4.4	3
118	Estimated Impact of Targeted Pre-Exposure Prophylaxis: Strategies for Men Who Have Sex with Men in the United States. <i>International Journal of Environmental Research and Public Health</i> , <b>2019</b> , 16,	4.6	8
117	Adherence to the iDSI reference case among published cost-per-DALY averted studies. <i>PLoS ONE</i> , <b>2019</b> , 14, e0205633	3.7	21
116	Trends of cost-effectiveness studies in sleep medicine. <i>Sleep Medicine</i> , <b>2019</b> , 53, 176-180	4.6	10
115	3385 TARGETING DIABETES PREVENTION PROGRAMS: INDIVIDUAL RISK-BASED HEALTH ECONOMIC ANALYSIS. <i>Journal of Clinical and Translational Science</i> , <b>2019</b> , 3, 155-156	0.4	78
114	Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?. <i>Value in Health</i> , <b>2019</b> , 22, 1396-1401	3.3	2
113	Targeted Incentive Programs For Lung Cancer Screening Can Improve Population Health And Economic Efficiency. <i>Health Affairs</i> , <b>2019</b> , 38, 60-67	7	6
112	Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. <i>Value in Health</i> , <b>2018</b> , 21, 759-761	3.3	71
111	Patient Variability Seldom Assessed in Cost-effectiveness Studies. <i>Medical Decision Making</i> , <b>2018</b> , 38, 487-494	2.5	12

110	A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures. <i>Value in Health</i> , <b>2018</b> , 21, 400-406	3.3	2
109	Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 212-221	4.5	7
108	Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis. <i>Annals of Internal Medicine</i> , <b>2018</b> , 168, 161-169	8	48
107	A Call for Open-Source Cost-Effectiveness Analysis. <i>Annals of Internal Medicine</i> , <b>2018</b> , 168, 529	8	4
106	Risk-Targeted Lung Cancer Screening. <i>Annals of Internal Medicine</i> , <b>2018</b> , 169, 200-201	8	1
105	Unintended consequences of the potential phase-out of gamma irradiation. <i>F1000Research</i> , <b>2018</b> , 7, 348	3.6	5
104	Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures. <i>Gates Open Research</i> , <b>2018</b> , 2, 5	2.4	13
103	Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures. <i>Gates Open Research</i> , <b>2018</b> , 2, 5	2.4	9
102	Are National Comprehensive Cancer Network (NCCN) Evidence Blocks (EB) Affordability Ratings (AR) representative of real-world costs? An evaluation of advanced non small cell lung cancer (aNSCLC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 6512-6512	2.2	
101	Cost-effectiveness of adjuvant chemotherapy in early stage breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e18887-e18887	2.2	
100	Assessing the risk of cardiac toxicity after contemporary treatment for Hodgkin lymphoma: a systematic review. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 1976-1980	1.9	2
99	QALYs in 2018-Advantages and Concerns. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 319, 2473-2474	27.4	75
98	Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value Frameworks. <i>Value in Health</i> , <b>2017</b> , 20, 193-199	3.3	13
97	Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs. <i>Value in Health</i> , <b>2017</b> , 20, 200-205	3.3	28
96	The influence of time horizon on results of cost-effectiveness analyses. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2017</b> , 17, 615-623	2.2	32
95	Understanding the Value of Individualized Information: The Impact of Poor Calibration or Discrimination in Outcome Prediction Models. <i>Medical Decision Making</i> , <b>2017</b> , 37, 790-801	2.5	5
94	Can Economic Model Transparency Improve Provider Interpretation of Cost-Effectiveness Analysis? A Response. <i>Medical Care</i> , <b>2017</b> , 55, 912-914	3.1	11
93	When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs. <i>PLoS Medicine</i> , <b>2017</b> , 14, e1002397	11.6	48

92	Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2017</b> , 23, S34-S48	1.9	12
91	Hospitalizations for ambulatory care sensitive conditions and unplanned readmissions among Medicare beneficiaries with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 1174-1178	1.2	29
90	ICER's Revised Value Assessment Framework for 2017-2019: A Critique. <i>Pharmacoeconomics</i> , <b>2017</b> , 35, 977-980	4.4	8
89	The Cost-Effectiveness of Oral Nutrition Supplementation for Malnourished Older Hospital Patients. <i>Applied Health Economics and Health Policy</i> , <b>2017</b> , 15, 75-83	3.4	28
88	Economic Evaluation in Adolescent and Young Adult Cancer: Methodological Considerations and the State of the Science. <i>Pediatric Oncology</i> , <b>2017</b> , 779-799	0.5	2
87	Validity and reliability of four value frameworks for cancer drugs.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 6603-6603	2.2	
86	Network meta-analysis of adjuvant chemotherapy in early breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e12071-e12071	2.2	
85	Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia: An Analysis of SEER-Medicare Data From 1995 to 2007. <i>Medical Care</i> , <b>2016</b> , 54, 380-5	3.1	10
84	A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted. <i>PLoS ONE</i> , <b>2016</b> , 11, e0168512	3.7	46
83	Assessing the Risk of Cardiac Toxicity after Contemporary Treatment for Hodgkin Lymphoma (HL): A Multidisciplinary Systematic Review. <i>Blood</i> , <b>2016</b> , 128, 3564-3564	2.2	
82	Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare. <i>Bone Marrow Research</i> , <b>2016</b> , 2016, 3645623		2
81	The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and Bangladesh. <i>Health Research Policy and Systems</i> , <b>2016</b> , 14, 86	3.7	6
80	O2-11-01: National Estimates of Potentially Avoidable Hospitalizations among Medicare Beneficiaries with Alzheimer's Disease and Related Dementias <b>2016</b> , 12, P253-P254		6
79	Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation Study. <i>Pharmacoeconomics</i> , <b>2016</b> , 34, 1255-1265	4.4	6
78	Medicare is scrutinizing evidence more tightly for national coverage determinations. <i>Health Affairs</i> , <b>2015</b> , 34, 253-60	7	24
77	Cost-utility analyses in diabetes: a systematic review and implications from real-world evidence. <i>Value in Health</i> , <b>2015</b> , 18, 308-14	3.3	25
76	Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results-Medicare Database. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 1823-9	4.7	26
75	The changing face of the cost-utility literature, 1990-2012. <i>Value in Health</i> , <b>2015</b> , 18, 271-7	3.3	71

74	Vascular access choice in incident hemodialysis patients: a decision analysis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2015</b> , 26, 183-91	12.7	89
73	Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. <i>Blood</i> , <b>2015</b> , 125, 1866-9	2.2	27
72	Cost estimation of first-line antiretroviral therapy with zidovudine/stavudine as the nucleoside backbone in India: a pilot study. <i>Journal of the International Association of Providers of AIDS Care</i> , <b>2015</b> , 14, 180-4	1.7	1
71	Price and value in cancer care. <i>Cancer</i> , <b>2015</b> , 121, 4097-8	6.4	
70	Toxicity and clinical outcomes in patients with HIV on zidovudine and tenofovir based regimens: a retrospective cohort study. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , <b>2015</b> , 109, 379-85	2	7
69	The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	26
68	The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2015</b> , 15, 931-40	2.2	16
67	Is the high cost of CML care "worth it"?. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e17801-e17801	2.2	1
66	An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy. <i>Blood</i> , <b>2015</b> , 126, 2635-2635	2.2	
65	Evaluation of the economic burden of diseases associated with poor nutrition status. <i>Journal of Parenteral and Enteral Nutrition</i> , <b>2014</b> , 38, 35S-41S	4.2	16
64	The Progression of Alzheimer's Disease Can Be Assessed with a Short Version of the CERAD Neuropsychological Battery: The Kuopio ALSOVA Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , <b>2014</b> , 4, 494-508	2.5	5
63	Updating cost-effectiveness--the curious resilience of the \$50,000-per-QALY threshold. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 796-7	59.2	1343
62	Unintended benefits: the potential economic impact of addressing risk factors to prevent Alzheimer's disease. <i>Health Affairs</i> , <b>2014</b> , 33, 547-54	7	18
61	FDA's proposed ban on trans fats: How do the costs and benefits stack up?. <i>Clinical Therapeutics</i> , <b>2014</b> , 36, 322-7	3.5	2
60	Survival benefit and cost of autologous hematopoietic stem cell transplantation (Auto HSCT) in elderly patients with multiple myeloma (MM) using the SEER-Medicare database.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8517-8517	2.2	
59	Pediatric Lipid Screening and Treatment for Cardiovascular Disease Prevention: An Ounce or a Pound?. <i>Current Cardiovascular Risk Reports</i> , <b>2013</b> , 7, 261-269	0.9	1
58	Illustrating potential efficiency gains from using cost-effectiveness evidence to reallocate Medicare expenditures. <i>Value in Health</i> , <b>2013</b> , 16, 629-38	3.3	15
57	Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disorders. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, 30-8	1.2	89

56	A role for research: an observation on preventive services for women. <i>American Journal of Preventive Medicine</i> , <b>2013</b> , 44, S12-5	6.1	7
55	Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2013</b> , 13, 513-22	2.2	8
54	A systematic review of the evidence concerning the economic impact of employee-focused health promotion and wellness programs. <i>Journal of Occupational and Environmental Medicine</i> , <b>2013</b> , 55, 209-22 <sup>2</sup>	5 <sup>1</sup>	
53	Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. <i>Health Economics (United Kingdom)</i> , <b>2012</b> , 21, 238-51	2.4	94
52	Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 1271-7	15.1	97
51	Cost-effectiveness in the contemporary management of critical limb ischemia with tissue loss. <i>Journal of Vascular Surgery</i> , <b>2012</b> , 56, 1015-24.e1	3.5	71
50	Cost-effectiveness of cardiovascular disease spending. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 2123-4	15.1	8
49	A primer on cost-effectiveness analyses for vascular surgeons. <i>Journal of Vascular Surgery</i> , <b>2012</b> , 55, 1794-800	11	
48	Toward modernizing the systematic review pipeline in genetics: efficient updating via data mining. <i>Genetics in Medicine</i> , <b>2012</b> , 14, 663-9	8.1	43
47	Cardiac screening prior to stimulant treatment of ADHD: a survey of US-based pediatricians. <i>Pediatrics</i> , <b>2012</b> , 129, 222-30	7.4	13
46	Policy: Rethink chemical risk assessments. <i>Nature</i> , <b>2012</b> , 489, 27-8	50.4	22
45	Survey of United States child and adolescent psychiatrists: Cardiac screening practices prior to starting patients on stimulants. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2012</b> , 22, 375-84	2.9	4
44	Costs and benefits of targeted screening for causes of sudden cardiac death in children and adolescents. <i>Circulation</i> , <b>2012</b> , 125, 2621-9	16.7	44
43	Electrocardiogram screening for disorders that cause sudden cardiac death in asymptomatic children: a meta-analysis. <i>Pediatrics</i> , <b>2012</b> , 129, e999-1010	7.4	63
42	Imputing productivity gains from clinical trials. <i>Journal of Occupational and Environmental Medicine</i> , <b>2012</b> , 54, 826-33	2	1
41	A clinical and economic evaluation of enteral nutrition. <i>Current Medical Research and Opinion</i> , <b>2011</b> , 27, 413-22	2.5	52
40	Regression analysis on the variation in efficiency frontiers for prevention stage of HIV/AIDS. <i>Journal of Medical Economics</i> , <b>2011</b> , 14, 187-93	2.4	3
39	Screening for sudden cardiac death in the young: report from a national heart, lung, and blood institute working group. <i>Circulation</i> , <b>2011</b> , 123, 1911-8	16.7	111

38	What is the value of oncology medicines?. <i>Nature Biotechnology</i> , <b>2010</b> , 28, 1160-3	44.5	12
37	The adoption of cost-effectiveness acceptability curves in cost-utility analyses. <i>Medical Decision Making</i> , <b>2010</b> , 30, 314-9	2.5	10
36	Little evidence of correlation between growth in health care spending and reduced mortality. <i>Health Affairs</i> , <b>2010</b> , 29, 1523-31	7	20
35	Comparative effectiveness of ST-segment-elevation myocardial infarction regionalization strategies. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2010</b> , 3, 506-13	5.8	38
34	Dependence as a unifying construct in defining Alzheimer@ disease severity. <i>Alzheimer@ and Dementia</i> , <b>2010</b> , 6, 482-93	1.2	43
33	Walking speed and economic outcomes for walking-impaired patients with multiple sclerosis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2010</b> , 10, 595-603	2.2	11
32	The empirical basis for determinations of medical futility. <i>Journal of General Internal Medicine</i> , <b>2010</b> , 25, 1083-9	4	44
31	Dioxin toxicity. <i>Risk Analysis</i> , <b>2010</b> , 30, 1457-8	3.9	
30	Low-value services in value-based insurance design. <i>American Journal of Managed Care</i> , <b>2010</b> , 16, 280-6	2.1	17
29	30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement. <i>Pharmacoeconomics</i> , <b>2009</b> , 27, 861-72	4.4	56
28	Decision analytic models for Alzheimer@ disease: state of the art and future directions. <i>Alzheimer@ and Dementia</i> , <b>2008</b> , 4, 212-22	1.2	36
27	Reexamining the emperor@ new clothes: ambiguities in current cardiac screening recommendations for youth with attention deficit hyperactivity disorder. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2008</b> , 1, 134-7	5.8	10
26	Using decision analysis to better evaluate pediatric clinical guidelines. <i>Health Affairs</i> , <b>2008</b> , 27, 1467-75	7	6
25	Does preventive care save money? Health economics and the presidential candidates. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 661-3	59.2	287
24	Dialysis facility ownership and epoetin dosing in hemodialysis patients: a medical economic perspective. <i>American Journal of Kidney Diseases</i> , <b>2007</b> , 50, 362-5	7.4	3
23	What@ more dangerous, your aspirin or your car? Thinking rationally about drug risks (and benefits). <i>Health Affairs</i> , <b>2007</b> , 26, 636-46	7	14
22	Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , <b>2007</b> , 10 Suppl 1, 1-269	8.6	559
21	Comparing patient access to pharmaceuticals in the UK and US. <i>Applied Health Economics and Health Policy</i> , <b>2006</b> , 5, 177-87	3.4	30



20	Author response: Risks and Benefits of Seafood Consumption. <i>American Journal of Preventive Medicine</i> , <b>2006</b> , 30, 441-443	6.1	4
19	Health trade-offs from policies to alter fish consumption. <i>American Journal of Preventive Medicine</i> , <b>2005</b> , 29, 324	6.1	12
18	A quantitative analysis of prenatal methyl mercury exposure and cognitive development. <i>American Journal of Preventive Medicine</i> , <b>2005</b> , 29, 353-65	6.1	106
17	A quantitative analysis of prenatal intake of n-3 polyunsaturated fatty acids and cognitive development. <i>American Journal of Preventive Medicine</i> , <b>2005</b> , 29, 366-74	6.1	131
16	A quantitative analysis of fish consumption and coronary heart disease mortality. <i>American Journal of Preventive Medicine</i> , <b>2005</b> , 29, 335-46	6.1	140
15	A quantitative analysis of fish consumption and stroke risk. <i>American Journal of Preventive Medicine</i> , <b>2005</b> , 29, 347-52	6.1	83
14	A quantitative risk-benefit analysis of changes in population fish consumption. <i>American Journal of Preventive Medicine</i> , <b>2005</b> , 29, 325-34	6.1	172
13	Diesel vs. compressed natural gas for school buses: a cost-effectiveness evaluation of alternative fuels. <i>Energy Policy</i> , <b>2005</b> , 33, 1709-1722	7.2	24
12	When is evidence sufficient?. <i>Health Affairs</i> , <b>2005</b> , 24, 93-101	0	65
11	Weight of the Evidence Evaluation of Low-Dose Reproductive and Developmental Effects of Bisphenol A. <i>Human and Ecological Risk Assessment (HERA)</i> , <b>2004</b> , 10, 875-921	4.9	76
10	A revised economic analysis of restrictions on the use of cell phones while driving. <i>Risk Analysis</i> , <b>2003</b> , 23, 5-17	3.9	57
9	Fuels for urban transit buses: a cost-effectiveness analysis. <i>Environmental Science &amp; Technology</i> , <b>2003</b> , 37, 1477-84	10.3	36
8	A comprehensive evaluation of the potential health risks associated with occupational and environmental exposure to styrene. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , <b>2002</b> , 5, 1-265	8.6	86
7	The development of a stochastic physiologically-based pharmacokinetic model for lead. <i>Science of the Total Environment</i> , <b>2001</b> , 274, 15-9	10.2	19
6	Likelihood Ratio Analysis of Skin Cancer Prevalence Associated with Arsenic in Drinking Water in the USA. <i>Environmental Geochemistry and Health</i> , <b>1998</b> , 20, 61-66	4.7	7
5	An Arsenic Exposure Model: Probabilistic Validation Using Empirical Data. <i>Human and Ecological Risk Assessment (HERA)</i> , <b>1998</b> , 4, 341-377	4.9	16
4	Life years lost at hazardous waste sites: remediation worker fatalities vs. cancer deaths to nearby residents. <i>Risk Analysis</i> , <b>1997</b> , 17, 419-25	3.9	18
3	Noncancer Risk Assessment: A Probabilistic Alternative to Current Practice. <i>Human and Ecological Risk Assessment (HERA)</i> , <b>1996</b> , 2, 79-102	4.9	105

- 2 The use of Monte Carlo simulation techniques to predict population blood lead levels.  
*Environmental Geochemistry and Health*, **1994**, 16, 197-215 4-7 1
- 1 Bovine Spongiform Encephalopathy: Risk Assessment and Governmental Policy 303-312